scholarly journals Natural Products for Antithrombosis

2015 ◽  
Vol 2015 ◽  
pp. 1-17 ◽  
Author(s):  
Cen Chen ◽  
Feng-Qing Yang ◽  
Qian Zhang ◽  
Feng-Qin Wang ◽  
Yuan-Jia Hu ◽  
...  
Keyword(s):  
Natural Products ◽  
Thrombus Formation ◽  
Coagulation System ◽  
Bioactive Components ◽  
Flow Conditions ◽  
Paper Briefly ◽  
Inflammatory Conditions ◽  
Antiplatelet Aggregation ◽  
Thrombotic Diseases

Thrombosis is considered to be closely related to several diseases such as atherosclerosis, ischemic heart disease and stroke, as well as rheumatoid arthritis, hyperuricemia, and various inflammatory conditions. More and more studies have been focused on understanding the mechanism of molecular and cellular basis of thrombus formation as well as preventing thrombosis for the treatment of thrombotic diseases. In reality, there is considerable interest in the role of natural products and their bioactive components in the prevention and treatment of thrombosis related disorders. This paper briefly describes the mechanisms of thrombus formation on three aspects, including coagulation system, platelet activation, and aggregation, and change of blood flow conditions. Furthermore, the natural products for antithrombosis by anticoagulation, antiplatelet aggregation, and fibrinolysis were summarized, respectively.

Absence of Fibrinogen in Afibrinogenemia Results in Large but Loosely Packed Thrombi under Flow Conditions

2001 ◽  
Vol 85 (04) ◽  
pp. 736-742 ◽  
Author(s):  
Ya-Ping Wu ◽  
Martin IJsseldijk ◽  
Jaap Zwaginga ◽  
Jan Sixma ◽  
Philip de Groot ◽  
...  
Keyword(s):  
Morphological Analysis ◽  
Surface Coverage ◽  
Thrombus Formation ◽  
Flow Conditions ◽  
Thrombotic Complications ◽  
Platelet Thrombus ◽  
The Difference ◽  
Adhesive Proteins ◽  
Lamellipodia Formation

SummaryWe studied the role of fibrinogen in platelet thrombus formation under flow on adhesive proteins using afibrinogenemic blood (LMWH anticoagulated) in a perfusion system. Perfusions with afibrinogenemic blood showed strong increased surface coverage and thrombus volume that normalized upon addition of fibrinogen. Similar studies using citrate anticoagulated blood showed that this was due to fibrinogen and not fibrin. Morphological analysis showed that afibrinogenemic thrombi were loosely packed and consisted mainly of dendritic platelets that contacted one another through filopodia. However, in the presence of fibrinogen, platelets formed lamellipodia and spread out on top of one another. Studies with radiolabeled platelets showed similar numbers of platelets in both conditions demonstrating that the difference is one of packing and the larger size is due to absence of lamellipodia formation and spreading. The found increased thrombus size and loosely packed platelets might help to understand thrombotic complications sometimes seen in afibrinogenemia patients.

Conditional Disruption of the Murine Prothrombin Gene.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 1600-1600
Author(s):  
Eric S. Mullins ◽  
Matthew J. Flick ◽  
Keith W. Kombrinck ◽  
Sandra J. Degen ◽  
William Sun ◽  
...  
Keyword(s):  
Thrombus Formation ◽  
Coagulation System ◽  
Compound Heterozygous ◽  
Bleeding Events ◽  
Protease Activated Receptors ◽  
Spontaneous Bleeding ◽  
Term Survival ◽  
Vascular Integrity

Abstract Thrombin is the core protease in the hemostatic system. Thrombin directs thrombus formation through the proteolytic conversion of fibrinogen to fibrin and the local activation of protease-activated receptors on platelets and other cells. In addition, thrombin controls the coagulation system through the activation of fXI, protein C and other key hemostatic factors. Interestingly, the biological role of thrombin is seemingly not limited to the maintenance of vascular integrity. There is appreciable evidence that thrombin-mediated proteolysis plays an important role in development, the inflammatory response, tissue repair, tumor cell metastasis and other physiological and pathological processes. Unfortunately, the embryonic and perinatal lethal phenotype previously described in prothrombin null (fII−/−) mice limited the utility of those knockout animals in better defining the larger role of fII in vivo. In order to develop the means to explore the importance of thrombin in disease processes within adult animals, a mouse line was generated carrying a conditional (“floxed”) fII knockout allele (fIIfx mice). Homozygous fIIfx/fx mice and compound heterozygous mice carrying one fII floxed allele and one fII null allele (fIIfx/− mice) developed to term, were present in offspring in the expected Mendelian frequencies, survived to adulthood and retained normal reproductive success. In the absence of Cre-mediated recombination, fIIfx/− mice maintained circulating fII levels that were low (approximately 10% of normal), but spontaneous bleeding events were never encountered in these animals. Studies of fIIfx/− mice carrying a Cre recombinase transgene known to be constitutively expressed in the liver showed that prothrombin levels can be reduced to levels incompatible with post-natal survival. More sophisticated studies using the polyI:C-inducible Mx-Cre system revealed that unchallenged Mx-Cre+/fIIfx/− mice consistently survived to adulthood. However, induction of Cre under conditions that result in near-complete recombination of target floxed alleles within the liver resulted in the development of spontaneous bleeding events and death within 7 days. Multiple sites of hemorrhage were evident in these challenged adults, including lower gastrointestinal and intracranial sites of bleeding. Immunological analysis of plasma collected from these animals revealed that they carried levels of fII below current detection limits (< 1% of normal). Studies are underway to establish both the lowest level of plasma fII compatible with long-term survival and define the effects of extremely low fII levels on disease processes in vivo.

FIBRONECTIN IS REQUIRED FOR PLATELET ADHESION AND FOR THROMBUS FORMATION ON SUBENDOTHELIUM AND COLLAGEN SURFACES

1987 ◽  
Author(s):  
E Bastida ◽  
G Escolar ◽  
R Castillo ◽  
A Ordinas ◽  
J J Sixma
Keyword(s):  
Platelet Adhesion ◽  
Thrombus Formation ◽  
Fibrillar Collagen ◽  
Flow Conditions ◽  
Shear Rates ◽  
Human Collagen ◽  
Platelet Thrombus ◽  
Computerized System ◽  
Total Coverage

Fibronectin (FN) plays a role in several adhesion mediated functions including the interaction of platelets with subendothelium.We investigated the role of plasma FN in platelet adhesion and platelet thrombus formation under flow conditions.To do this we used two different perfusion models:1)the annular chamber with α -chymotrypsin-treated rabbit vessel segments and 2)the flat chamber with coverslips coated with fibrillar purified human collagen type III.Perfusates consisted of washed platelets, and washed red blood celIs,suspended in normal or FN-depleted plasma.Perfusions were carried out for 10 min at shear rates of 300 or 1300 sec™1 Platelet deposition and thrombus dimensions were morphometrically evaluated by a computerized system. We found that depletion of plasma FN significantly reduced the percentage of total coverage surface and percentage of platelet thrombus, at both shear rates studied, and in both perfusion systems (p < 0.01)(p < 0.01).The dimensions of the platelet thrombi formed in perfusions at high shear rate were also significantly reduced in perfusions carried out with FN-depleted plasma.(p < 0.01). Addition of purified FN to FN-depleted perfusates restored all the values to those measured in the control perfusions.These results indicate that, in addition to supporting platelet adhesion to the subendothelium and to fibrillar collagen, FN contributes to platelet thrombus formation under flow conditions.

scholarly journals Antithrombin and Its Role in Host Defense and Inflammation

2021 ◽  
Vol 22 (8) ◽  
pp. 4283
Author(s):  
Christine Schlömmer ◽  
Anna Brandtner ◽  
Mirjam Bachler
Keyword(s):  
Cell Walls ◽  
Inflammatory Diseases ◽  
Antibacterial Properties ◽  
Coagulation System ◽  
Peptide Fragments ◽  
Inflammatory Signaling ◽  
Surface Receptors ◽  
Inflammatory Conditions ◽  
Randomized Control

Antithrombin (AT) is a natural anticoagulant that interacts with activated proteases of the coagulation system and with heparan sulfate proteoglycans (HSPG) on the surface of cells. The protein, which is synthesized in the liver, is also essential to confer the effects of therapeutic heparin. However, AT levels drop in systemic inflammatory diseases. The reason for this decline is consumption by the coagulation system but also by immunological processes. Aside from the primarily known anticoagulant effects, AT elicits distinct anti-inflammatory signaling responses. It binds to structures of the glycocalyx (syndecan-4) and further modulates the inflammatory response of endothelial cells and leukocytes by interacting with surface receptors. Additionally, AT exerts direct antimicrobial effects: depending on AT glycosylation it can bind to and perforate bacterial cell walls. Peptide fragments derived from proteolytic degradation of AT exert antibacterial properties. Despite these promising characteristics, therapeutic supplementation in inflammatory conditions has not proven to be effective in randomized control trials. Nevertheless, new insights provided by subgroup analyses and retrospective trials suggest that a recommendation be made to identify the patient population that would benefit most from AT substitution. Recent experiment findings place the role of various AT isoforms in the spotlight. This review provides an overview of new insights into a supposedly well-known molecule.

scholarly journals Endothelial cells and coagulation

2021 ◽  
Author(s):  
Katharina Neubauer ◽  
Barbara Zieger
Keyword(s):  
Endothelial Cells ◽  
Thrombus Formation ◽  
Platelet Inhibition ◽  
Coagulation Cascade ◽  
Coagulation System ◽  
Support Surface ◽  
Blood Fluidity ◽  
Tissue Factor Pathway ◽  
Pathway Inhibition

AbstractEndothelial cells form a monolayer, which lines blood vessels. They are crucially involved in maintaining blood fluidity and providing controlled vascular hemostasis at sites of injury. Thereby endothelial cells facilitate multiple mechanisms, including both procoagulant and anticoagulant, which must be kept in balance. Under physiological conditions, endothelial cells constitute a nonadhesive surface preventing activation of platelets and the coagulation cascade. Multiple fibrinolytic and antithrombotic properties act on their cell surface contributing to the maintenance of blood fluidity. These include platelet inhibition, the heparin-antithrombin III system, tissue factor pathway inhibition, thrombomodulin/protein C system, and fibrinolytic qualities. At sites of vascular damage, platelets react immediately by adhering to the exposed extracellular matrix, followed by platelet-platelet interactions to form a clot that effectively seals the injured vessel wall to prevent excessive blood loss. For solid thrombus formation, functional platelets are essential. In this process, endothelial cells serve as a support surface for formation of procoagulant complexes and clotting. This review gives an overview about the central role of the endothelium as a dynamic lining which controls the complex interplay of the coagulation system with the surrounding cells.

scholarly journals Distinct Localization of Coagulation Factor VIII, Von Willebrand Factor and Factor VIIIa-Mimetic Bispecific Antibody Contributing to Thrombus Formation Under Whole Blood Flow Conditions

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 1483-1483
Author(s):  
Yasuaki Shida ◽  
Keiji Nogami ◽  
Hiroaki Minami ◽  
Hiroaki Yaoi ◽  
Tomoko Matsumoto ◽  
...  
Keyword(s):  
Shear Flow ◽  
Research Funding ◽  
Hemophilia A ◽  
Thrombus Formation ◽  
Flow Chamber ◽  
High Shear ◽  
Flow Conditions ◽  
Von Willebrand ◽  
Low Shear

Abstract Background Factor VIII (FVIII) is an essential factor for coagulation system in the intrinsic pathway. Due to the short survival of FVIII in the plasma circulation, it requires von Willebrand factor (VWF) as a carrier protein to maintain the optimal level for hemostasis. VWF also plays an important role in primary hemostasis by bridging platelets to exposed subendothelial collagens, especially under high shear flow environment. Since VWF carries FVIII, it is conceivable that VWF takes FVIII to the sites of vascular injury. However, the role of FVIII at the local sites under flow conditions is not fully understood despite of the fact that increased level of FVIII is associated with the risk of venous thrombosis and the deficiency of FVIII is the pathology of the bleeding disorder, hemophilia A. The treatment of hemophilia A largely depends on the infusion of FVIII concentrates, which is often complicated by the development of the inhibitor. Recently, bispecific antibody（ACE910）that mimics the role of FVIIIa by recognizing FIXa and FX has been developed and is currently under clinical trial. This antibody theoretically works regardless of the presence of devastating inhibitors against FVIII. Furthermore, it could also improve the clinical outcome of the other bleeding disorders, such as von Willebrand disease (VWD). Aim To analyze the role of FVIII and VWF, and impact of ACE910 at the sites of vascular injury under various shear conditions, we have developed the flow-mediated thrombosis model using flow chamber system. Method Whole blood obtained from healthy donors, hemophilia A and VWD patients were perfused into the collagen coated flow chamber under high (2,500s-1) or low shear (50s-1) flow conditions with/without FVIII concentrate, FVIII/VWF concentrate and ACE910. Formed thrombus was fixed and immunostaining was performed with phalloidin (Platelet), anti-FVIII antibody (FVIII) and anti-thrombin antibody (Thrombin). For the detection of ACE910, anti-human IgG or anti-ACE antibody (rAQ8 or rAJ540) were used. Size of thrombi and distribution of platelet, FVIII, thrombin and ACE910 were analyzed. Result 1) Under high shear flow, thrombus formation of VWD blood was significantly impaired while blood from Hemophilia A demonstrated nearly normal thrombus formation. Addition of FVIII/VWF but not FVIII concentrate to the blood of these patients rescued the impaired thrombus formation. ACE910 enhanced the thrombus formation of blood from both VWD and hemophilia A. Under low shear flow, blood from both hemophilia A and VWD demonstrated decreased thrombus formation. FVIII, FVIII/VWF concentrates and ACE910 improved the size of thrombus. 2) Localization of FVIII was evaluated with thrombin as a marker for the activation of coagulation. Platelets and thrombin demonstrated complete co-localization and intensity of thrombin staining was associated with thrombus size. VWF localized mainly outer layer of thrombus and FVIII localized in and around thrombus. At high shear condition, FVIII and VWF mostly existed with platelets. By contrast, FVIII and VWF demonstrated less co-localization with platelets under low shear condition. ACE910 demonstrated similar tendency to FVIII localization although ACE910 did not appear around thrombus. Conclusion We have developed the flow chamber system to evaluate the extent of thrombogenesis under various shear environment. VWF showed dominant role under high shear conditions while FVIII plays a key role under low shear conditions. FVIII, VWF and ACE910 demonstrated distinct localization. Interestingly, the distribution of FVIII was broader than VWF and platelet. FVIII localized to platelets presumably prior to its activation and contributed for the subsequent thrombin generation at local sites. Finally, ACE910 demonstrated consistent enhancement of thrombus formation of blood from both hemophilia A and VWD and, therefore, is prompted for the treatment of these bleeding disorders. Disclosures Shida: Chugai Pharmaceutical Co., Ltd.: Research Funding. Nogami:Chugai Pharmaceutical Co., Ltd.: Membership on an entity's Board of Directors or advisory committees, Research Funding. Minami:Chugai Pharmaceutical Co., Ltd.: Research Funding. Yaoi:Chugai Pharmaceutical Co., Ltd.: Research Funding. Matsumoto:Chugai Pharmaceutical Co., Ltd.: Research Funding. Kitazawa:Chugai Pharmaceutical Co., Ltd.: Employment, Equity Ownership, Patents & Royalties. Hattori:Chugai Pharmaceutical Co., Ltd.: Employment, Equity Ownership, Patents & Royalties. Shima:Chugai Pharmaceutical Co., Ltd.: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.

Abstract 605: Activation of NLRP3 Inflammasome Complex Regulates the Onset of Hypoxia Induced Thrombosis

2015 ◽  
Vol 35 (suppl_1) ◽  
Author(s):  
Neha Gupta ◽  
Manish Sharma ◽  
Tathagata Chatterjee ◽  
Tarun Tyagi ◽  
Anita Sahu ◽  
...  
Keyword(s):  
Platelet Aggregation ◽  
Nlrp3 Inflammasome ◽  
Thrombus Formation ◽  
Vena Cava ◽  
Early Response ◽  
Sterile Inflammation ◽  
Coagulation System ◽  
Additional Risk Factor ◽  
Whole Transcriptome Analysis

Objective: Besides well known predisposing conditions such as cancer, diabetes, cardiovascular disease and surgery; hypoxia per se has been suggested to be an additional risk factor for venous thrombosis (VT). We have recently shown that hypoxia, either localized due to stasis, or systemic, due to environmental factors such as high altitude exposure, results in a prothrombotic milieu. The proteomic analysis implicated some novel plasma factors that could trigger thrombotic propensity; however, the exact mechanism involved still remains poorly understood. Methods & Results: Effect of hypoxia on coagulation system was analysed using inferior vena cava ligation and simulated hypobaric hypoxia rat models. Data demonstrated that hypoxia modulates both coagulation and fibrinolytic pathways and thrombus developed under hypoxic atmospheres is an aggravated form of thrombus progression under normoxic environments. Moreover, the whole transcriptome analysis using RNA sequencing approach implicated the novel role of NOD Like receptors3 (NLRP3) and inflammasome in thrombus formation suggesting the hypoxia induced thrombosis to be an episode of sterile inflammation. The cytokine array profiling and immunofloroscence data also supported the role of innate immune components. Both pharmacological inhibition and siRNA mediated knockdown of caspase-1 and NLRP-3 respectively reinforced that the activation of NLRP3-inflammasome complex critically regulates thrombogenesis in response to hypoxia. This complex is likely to be activated as an early response to hypoxia, which precedes the platelet aggregation and hence, onset of thrombosis. The translational implication of this novel finding was evident by activation of NLRP3 inflammasome components in human patients who developed VT under hypoxic environments. Conclusions: The current study reveals a novel role of NLRP3 inflammasome in thrombosis induced by localised as well as systemic hypoxic environments. Further, the production of IL-1β by NLRP3 inflammasome augments platelet aggregation, the key event for thrombogenesis.

scholarly journals Fibronectin is required for platelet adhesion and for thrombus formation on subendothelium and collagen surfaces

Blood ◽  
1987 ◽  
Vol 70 (5) ◽  
pp. 1437-1442 ◽  
Author(s):  
E Bastida ◽  
G Escolar ◽  
A Ordinas ◽  
JJ Sixma
Keyword(s):  
Platelet Adhesion ◽  
Thrombus Formation ◽  
Flow Conditions ◽  
Shear Rates ◽  
Platelet Aggregate ◽  
Human Collagen ◽  
Platelet Thrombus ◽  
Computerized System ◽  
Total Coverage

Abstract Fibronectin (FN) plays a role in several adhesion mediated functions including the interaction of platelets with subendothelium. We investigated the role of plasma FN in platelet adhesion and platelet thrombus formation under flow conditions. We used two different perfusion models: the annular chamber with alpha-chymotrypsin-treated rabbit vessel segments, and the flat chamber with coverslips coated with fibrillar purified human collagen type III. Perfusates consisted of washed platelets and washed RBCs, suspended in normal or FN-depleted plasma. Perfusions were carried out for ten minutes at shear rates of 300 or 1,300 s-1. Platelet deposition and thrombus dimensions were evaluated morphometrically by a computerized system. We found that depletion of plasma fibronectin significantly reduced the percentage of total coverage surface and percentage of platelet thrombus, at both shear rates studied, and in both perfusion systems (P less than .01) (P less than .01). The dimensions of the platelet thrombi formed in perfusions at high shear rate were also significantly reduced in perfusions carried out with FN depleted plasma (P less than .01). Addition of purified FN to FN-depleted perfusates restored all values to those measured in the control perfusions. These results indicate that plasma FN is required for platelet aggregate and thrombus formation following adhesion under flow conditions.

scholarly journals Natural Products in the Prevention of Metabolic Diseases: Lessons Learned from the 20th KAST Frontier Scientists Workshop

Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1881
Author(s):  
Seung J. Baek ◽  
Bruce D. Hammock ◽  
In-Koo Hwang ◽  
Qingxiao Li ◽  
Naima Moustaid-Moussa ◽  
...  
Keyword(s):  
Natural Products ◽  
Metabolic Diseases ◽  
Current Knowledge ◽  
Analytical Techniques ◽  
Lessons Learned ◽  
Bioactive Components ◽  
Underlying Causes ◽  
The University ◽  
And Oxidative Stress

The incidence of metabolic and chronic diseases including cancer, obesity, inflammation-related diseases sharply increased in the 21st century. Major underlying causes for these diseases are inflammation and oxidative stress. Accordingly, natural products and their bioactive components are obvious therapeutic agents for these diseases, given their antioxidant and anti-inflammatory properties. Research in this area has been significantly expanded to include chemical identification of these compounds using advanced analytical techniques, determining their mechanism of action, food fortification and supplement development, and enhancing their bioavailability and bioactivity using nanotechnology. These timely topics were discussed at the 20th Frontier Scientists Workshop sponsored by the Korean Academy of Science and Technology, held at the University of Hawaii at Manoa on 23 November 2019. Scientists from South Korea and the U.S. shared their recent research under the overarching theme of Bioactive Compounds, Nanoparticles, and Disease Prevention. This review summarizes presentations at the workshop to provide current knowledge of the role of natural products in the prevention and treatment of metabolic diseases.

Activated FVIII Released from FVIII/VWF Complex Facilitates Thrombus Development Under High Shear Flow Condition

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 83-83
Author(s):  
Hiroaki Yaoi ◽  
Yasuaki Shida ◽  
Takehisa Kitazawa ◽  
Kunihiro Hattori ◽  
Midori Shima ◽  
...  
Keyword(s):  
Board Of Directors ◽  
Research Funding ◽  
Thrombus Formation ◽  
High Shear ◽  
Flow Conditions ◽  
Advisory Committees ◽  
Platelet Surface ◽  
Chugai Pharmaceutical ◽  
Low Shear

Abstract Background : Factor VIII (FVIII) is protected by binding to its carrier protein, von Willebrand factor (VWF) in the circulation. VWF contributes to hemostasis particularly under high shear flow condition by extending its multimeric configuration. By contrast, coagulation factors including FVIII are thought to play a dominant role under low shear. Since FVIII binds to VWF unlike other coagulation factors, FVIII may contribute to thrombus formation even under high shear conditions. FVIII has to be released from VWF and activated to exert its coagulation function. However, the role of interaction between FVIII and VWF on hemostasis under flow conditions needs to be explored in addition to the protective function of VWF. Aims: To analyze the mechanism and role of FVIII and VWF interaction on hemostasis under flow conditions. Methods: Whole blood samples were obtained from patients with type 2A von Willebrand disease (VWD). FVIII, VWF, FVIII/VWF (final concentration; f.c. 1U/mL), FVIII plus ESH8 (f.c. 1 µM), and emicizumab (ACE910; f.c. 100 µg/mL) were added to the blood followed by perfusion into the collagen-coated flow chamber under controlled high (2,500s-1) and low (50s-1) shear conditions. ESH8 is an anti-FVIII antibody that interrupts the release of FVIII from VWF, and emicizumab is a bispecific antibody mimicking activated FVIII (FVIIIa). The concentration of emicizumab was chosen, as it was the highest dose in clinical study. After the perfusion, formed thrombus was fixed and immunostaining was performed to visualize platelets, VWF, thrombin, and FVIII. Thrombi were observed by using confocal laser scanning microscopy and the obtained images were analyzed by Image Pro Premier 3D. Initial thrombus formation was measured as surface coverage (SC) and thrombus development was measured as thrombus volume (TV). Results: SC and TV were impaired in VWD particularly under high shear (high: SC 8.3%, TV 3.9x103μm3, low: SC 2.7%, TV 2.9x103μm3). Addition of FVIII/VWF improved thrombus formation to normal level under both shear conditions (high: SC 37.3%, TV 2.4x104μm3, low SC 4.3%, TV 4.1x103μm3). Addition of VWF improved SC and TV under both shear conditions (high: 40.9%, 1.7x104μm3, low: SC 3.0%, TV 3.3x103μm3), suggesting that the VWF function was crucial under both shear. By contrast, addition of FVIII alone did not improve SC and TV under both shears (high: SC 9.9%, TV 5.0x103μm3, low: SC 2.4%, TV 3.1x103μm3). Since FVIII/VWF had a greater effect on TV than VWF alone, FVIII enhanced thrombus development under high shears, however, this effect required the presence of VWF. FVIII immunostaining demonstrated the binding of FVIII on platelet surface in the FVIII-added experiment and, therefore, FVIII binding alone was not sufficient to initiate coagulation. Since FVIII may need to be activated on the platelet surface in a timely fashion, it was speculated that the optimal delivery from VWF and activation of FVIII on platelets was required for hemostasis. To analyze the role of FVIII and VWF interaction on hemostasis under flow condition, ESH8 was used to modify FVIII/VWF binding by blocking FVIII release. Treatment of FVIII/VWF with ESH8 did not change SC but slightly impaired TV under high shear (high: SC 41.8%, TV 1.8 x104μm3). Thus, the presence of FVIII at thrombus was not enough and the release of FVIII from VWF and presumably activation of FVIII on the platelet surface might be essential for thrombus formation under high shear. Under low shear, both SC and TV were interrupted by ESH8 (SC 2.6%, TV 3.1x103μm3), suggesting the important role of FVIII and coagulation under low shear. Lastly, to analyze the impact of activated FVIII on thrombus formation under flow conditions, emicizumab was evaluated in this system. In contrast to FVIII, emicizumab alone improved thrombus formation (high: SC 26.0%, TV 1.1 x104μm3, low: SC 3.5%, TV 4.2 x103μm3). The rate of improvement in SC and TV was better under low shear than high shear, which implicated the coagulative role of emicizumab. Even under high shear, however, emicizumab enhanced thrombus formation. Therefore, the role of emicizumab in substituting for the activated form of FVIII might be able to rapidly initiate coagulation even under high shear. Conclusion: VWF delivers and releases FVIII in a timely fashion on platelet surface. FVIII has to become active on platelets for hemostasis and FVIIIa can accelerate thrombus formation even under high shear condition. Disclosures Yaoi: Chugai Pharmaceutical Co., Ltd.: Research Funding. Shida:Chugai Pharmaceutical Co., Ltd.: Research Funding. Kitazawa:Chugai Pharmaceutical Co.: Employment, Equity Ownership, Patents & Royalties; Sysmex Corporation: Patents & Royalties. Hattori:Chugai Pharmaceutical Co.: Employment, Equity Ownership, Patents & Royalties. Shima:Sysmex Corporation: Patents & Royalties, Research Funding; Chugai Pharmaceutical Co., Ltd.: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding; F. Hoffmann-La Roche Ltd.: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Nogami:F. Hoffmann-La Roche Ltd.: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sysmex Corporation: Patents & Royalties, Research Funding; Chugai Pharmaceutical Co., Ltd.: Honoraria, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding.

Sign in / Sign up

Export Citation Format

Share Document